Survey of Ophthalmology
Volume 47 , Pages S65-S76 , August 2002

The Effect of Latanoprost on Intraocular Pressure During 2 Years of Treatment

  • Katarina Hedman, MSc

      Affiliations

    • Corresponding Author InformationReprint address: Katarina Hedman, UF35-2, Pharmacia Diagnostics, S-751 82 Uppsala, Sweden
    • Department of Neuro Science Ophthalmology, University Hospital, Uppsala, Sweden
    • Pharmacia Diagnostics, Uppsala, Sweden
    • ,
  • Peter G. Watson, FRCS

      Affiliations

    • Addenbrooke's Hospital, Cambridge, United Kingdom
    • ,
  • Albert Alm, MD

      Affiliations

    • Department of Neuro Science Ophthalmology, University Hospital, Uppsala, Sweden

References 

  1. The advanced glaucoma intervention study (AGIS) (7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators). Am J Ophthalmol. 2000;130:429–440
  2. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol. 1998;12:498–505
  3. Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology. 1995;102:1743–1752
  4. Alm A, Villumsen J. PhXA34, a new potent ocular hypotensive drug. A study on dose-response relationship and on aqueous humor dynamics in healthy volunteers. Arch Ophthalmol. 1991;109:1564–1568
  5. Alm A, Widengard I. Latanoprost (experience of 2-year treatment in Scandinavia). Acta Ophthalmol Scand. 2000;78:71–76
  6. Boger WP, Puliafito CA, Steinert RF, Langston DP. Long-term experience with timolol ophthalmic solution in patients with open-angle glaucoma. Ophthalmology. 1978;85:259–267
  7. Crawford K, Kaufman PL. Pilocarpine antagonizes prostaglandin F2 alpha-induced ocular hypotension in monkeys. Evidence for enhancement of Uveoscleral outflow by prostaglandin F2 alpha. Arch Ophthalmol. 1987;105:1112–1116
  8. Gabelt BT, Kaufman PL. Prostaglandin F2 alpha increases uveoscleral outflow in the cynomolgus monkey. Exp Eye Res. 1989;49:389–402
  9. Gandolfi SA. Restoring sensitivity to timolol after long-term drift in primary open- angle glaucoma. Invest Ophthalmol Vis Sci. 1990;31:354–358
  10. Hedman K, Alm A. A pooled data analysis of three randomised, double-masked six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol. Eur J Ophthalmol. 2000;2:94–104
  11. Kobelt-Nguyen G, Gerdtham UG, Alm A. Costs of treating primary open-angle glaucoma and ocular hypertension (a retrospective, observational two-year chart review of newly diagnosed patients in Sweden and the United States). J Glaucoma. 1998;7:95–104
  12. Lee TL. Identification of prognostic factors related to survival time. In:  Lee TL editors. Statistical Methods for Survival Data Analysis. New York: Wiley-Interscience; 1992;p. 243–279 ed 2,
  13. Lee TL. Nonparametric methods of estimating survival functions. In:  Lee TL editors. Statistical Methods for Survival Data Analysis. New York: Wiley-Interscience; 1992;p. 66–101 ed 2,
  14. MacMahon S, Peto R, Cutler J, et al.  Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure (prospective observational studies corrected for the regression dilution bias). Lancet. 1990;335:765–774
  15. Migdal C, Gregory W, Hitchings R. Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. Ophthalmology. 1994;101:1651–1656 discussion 1657
  16. Milliken GA, Johnson DE. Analyzing split-plot and certain repeated measures experiments with unbalanced and missing data. In:  Milliken GA,  Johnson DE editor. Analysis of Messy Data. New York: Chapman & Hall; 1992;p. 377–407
  17. Nilsson SF, Samuelsson M, Bill A, Stjernschantz J. Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2 alpha-1-isopropylester in the cynomolgus monkey. Exp Eye Res. 1989;48:707–716
  18. Ocklind A. Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections. Exp Eye Res. 1998;67:179–191
  19. Quigley HA, Tielsch JM, Katz J, Sommer A. Rate of progression in open-angle glaucoma estimated from cross-sectional prevalence of visual field damage. Am J Ophthalmol. 1996;122:355–363
  20. Ray WA, O'Day DM, Head WS, Robinson R. Statistical analysis for experimental models of ocular disease (continuous response measures). Curr Eye Res. 1985;4:585–597
  21. Resul B, Stjernschantz J, No K, et al.  Phenyl-substituted prostaglandins (potent and selective antiglaucoma agents). J Med Chem. 1993;36:243–248
  22. Rouland JF, Hågå A, Bengtsson S, et al.  What triggers change in therapy?. In:  Jönsson B,  Krieglstein G editor. Primary Open-angle Glaucoma. Differences in International Treatment Patterns and Costs. Oxford: ISIS Medical Media Ltd; 1998;p. 163–169
  23. Schachtschabel U, Lindsey JD, Weinreb RN. The mechanism of action of prostaglandins on uveoscleral outflow. Curr Opin Ophthalmol. 2000;11:112–115
  24. Sommer A, Tielsch JM, Katz J, et al.  Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey. Arch Ophthalmol. 1991;109:1090–1095
  25. Stjernschantz J, Resul B. Phenyl substituted prostaglandin analogs for glaucoma treatment. Drugs Future. 1992;8:691–704
  26. Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology. 1993;100:1297–1304
  27. Watson P, Stjernschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology. 1996;103:126–137
  28. Watson PG, Barnett MF, Parker V, Haybittle J. A 7 year prospective comparative study of three topical beta blockers in the management of primary open angle glaucoma. Br J Ophthalmol. 2001;85:962–968
  29. Watson PG. Latanoprost. Two years experience of its use in the United Kingdom. Latanoprost Study Group. 1998;Ophthalmology 105:82–87
  30. Wistrand PJ, Stjernschantz J, Olsson K, et al.  The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol. 1997;41(Suppl 2):S129–S138
  31. Ziai N, Dolan JW, Kacere RD, Brubaker RF. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol. 1993;111:1351–1358

☆ Supported by Pharmacia Corporation, Peapack, New Jersey, USA. Dr. Alm is a consultant to Pharmacia Corporation, Stockholm, Sweden. Katarina Hedman is employed by Pharmacia Diagnostics, Uppsala, Sweden. None of the authors reported any proprietary interest in the development or marketing of drugs used in the clinical trials subject to the pooled data analysis. The authors thank Adam Taube, PhD, Department of Information Science—Statistics, Uppsala University, Uppsala, Sweden.

PII: S0039-6257(02)00301-6

Survey of Ophthalmology
Volume 47 , Pages S65-S76 , August 2002

Article Tools

* Image Usage & Resolution